Dr. Reddy seeks nod for DCGI approval for Phase 3 clinical trials of Sputnik V in India

Dr Reddy’s Laboratories has applied permission to the Drugs Controller General of India (DCGI) for conducting the phase-3 human clinical trials of Sputnik V, Russian coronavirus vaccine against COVID-19 in India, according to the sources.

“Dr Reddy’s Laboratories has applied to the DCGI seeking permission to conduct phase-3 human clinical trials of the Sputnik V vaccine against COVID-19 developed by Russia. The DCGI will carry out a technical evaluation of the application before giving its approval,” according to the sources.

Dr. Reddy has partnered with Russian Direct Investment Fund (RDIF) to conduct clinical trials of Sputnik V as well as its distribution.
Upon regulatory approval in India, RDIF will supply to Dr Reddy’s 100 million doses of the vaccine, the firm said last month.

Related Posts

  • Pharma
  • June 18, 2025
  • 79 views
Glenmark Pharma: FDA concludes inspection at US facility, issues five observations

Glenmark Pharmaceuticals said that the United States’ Food and Drug Administration (FDA) has concluded inspection of its manufacturing facility in Monroe, North Carolina. Glenmark Pharmaceuticals said that the United States’…

  • Pharma
  • June 18, 2025
  • 68 views
ED conducts searches across six States in drug trafficking case

The Enforcement Directorate on Tuesday conducted searches at 15 locations, including the premises of five pharmaceutical companies, across six States in connection with a drug trafficking case registered in Punjab.…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Glenmark Pharma: FDA concludes inspection at US facility, issues five observations

Glenmark Pharma: FDA concludes inspection at US facility, issues five observations

ED conducts searches across six States in drug trafficking case

ED conducts searches across six States in drug trafficking case

Gurugram: Teen dies after ‘friendly’ blow to chest; hospital role under scanner

Gurugram: Teen dies after ‘friendly’ blow to chest; hospital role under scanner

Biocon launches Rs 4,500-crore QIP; to issue 11.6% of equity base

Biocon launches Rs 4,500-crore QIP; to issue 11.6% of equity base